AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SHC · NASDAQ · Medical - Diagnostics & Research

Sotera Health

Provides contract sterilization, gamma technologies, and testing services for healthcare-product safety.

$19.27

After-hours close0.00 (0.00%)

At close$19.27(−1.08%)

Something off on this page? Send us feedback.

Profile

Sotera Health CompanySHCHealth Care

Connects Sterigenics contract sterilization, Nordion gamma technologies and Cobalt-60, and Nelson Labs testing and advisory services. Its three reported businesses form an end-to-end platform for healthcare-product sterilization and safety.

Sterigenics provides contract sterilization for healthcare products. Nordion supplies gamma technologies and Cobalt-60, while Nelson Labs provides testing and advisory services for product safety. Together, their services cover sterilization and safety work across healthcare products.

The three reported businesses form an end-to-end healthcare-product sterilization and safety platform. Sterigenics is the largest revenue contributor, and the platform supports healthcare-product safety worldwide.

These businesses combine legacy specialist capabilities under a public parent rather than operating as informal brands. EO-related claims and the company’s voluntary emission-control investments remain a structural part of the operating context.

Company facts

CEOAlton Shader

ListedNov 20, 2020

ExchangeNASDAQ

HeadquartersBroadview Heights, OH

CountryUnited States

Employees3,000

CIK0001822479

ISINUS83601L1026

Key statistics

Market cap$5.50B

EPS (ttm)$0.5724

P/E (ttm)33.67

ROE26.7%

P/B8.27

P/S4.52

Dividend yield—

Beta1.03vs XLV 0.63

Year to date +8.9% · Average volume (30d) 2.9M

Analysts

Price target, next 12 months$19.00−1.4%Median of 12 analysts · vs the Aug 28 close

ConsensusBuy11 of 12 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $19.27

High$20.00+3.8%

Median$19.00−1.4%

Low$18.00−6.6%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jun 24, 2026	UBS	Target				$19
Jun 5, 2026	Goldman Sachs	Reiterate		Buy	$17	$20
Apr 14, 2026	Barclays	Reiterate		Overweight	$20	$18
Jan 9, 2026	Piper Sandler	Upgrade	Neutral	Overweight	$17	$24
Jan 8, 2026	RBC Capital	Target			$17	$24

Earnings

EPS

Estimate$0.27

ReportedDue Nov 3, 2026

Revenue

Estimate$319.8M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$0.24	$0.26	+8.8%	$309.7M	$321.4M	+3.8%	+5.17%
May 5, 2026Q1 FY26	$0.17	$0.18	+5.9%	$270.8M	$280.0M	+3.4%	+3.07%
Feb 24, 2026Q4 FY25	$0.24	$0.26	+8.3%	$299.5M	$303.4M	+1.3%	−3.35%
Nov 4, 2025Q3 FY25	$0.22	$0.26	+18.2%	$299.6M	$311.3M	+3.9%	−3.77%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$254.5M	$294.3M	$311.3M	$303.4M	$280.0M	$321.4M
Gross profit	$135.4M	$166.6M	$177.6M	$165.9M	$144.0M	$178.0M
Operating income	$57.0M	$88.4M	$111.2M	$136.1M	$86.6M	$106.8M
Net income	−$13.3M	$8.0M	$48.4M	$34.8M	$26.6M	$53.6M
Diluted EPS	−$0.05	$0.03	$0.17	$0.12	$0.09	$0.19
Gross margin	53.2%	56.6%	57.0%	54.7%	51.4%	55.4%
Operating margin	22.4%	30.0%	35.7%	44.9%	30.9%	33.2%

Fiscal years (4-quarter sums)FY21 $931.5M · FY22 $1.00B · FY23 $1.05B · FY24 $1.10B · FY25 $1.16B

Revenue by product · Q2 FY26

Service$278.3M · 87%

Product$43.1M · 13%

Revenue by geography · FY25

United States$629.5M · 54%

Europe$232.2M · 20%

Canada$221.9M · 19%

Other Geographical Areas$79.9M · 7%

Balance sheet, Jun 30, 2026Cash & short-term investments $356.7M · Total debt $2.27B · Total assets $3.31B · Shareholders' equity $665.6M

Dividends

No dividends on record.

Ownership

Institutions 106.22%Insiders 2.29%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 285.17M · Float 154.14M · 54.1% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
WP XI Partners, L.P.	73.04M	25.70%	13G	Nov 12, 2025
Sessa Capital Im, L.P.	27.05M	9.49%	13F	Aug 14, 2026
Darsana Capital Partners LP	27.00M	9.47%	13F	Aug 14, 2026
BlackRock, Inc.	24.15M	8.47%	13F	Aug 7, 2026
Sculptor Capital LP	24.00M	8.42%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 17, 2026	Michael B. Jr. Petras	director, officer: Executive Chairman	−1,144,515	$18.50
Aug 7, 2026	Michael P. Rutz	officer: President of Sterigenics	−150,000	$18.84
May 13, 2026	GTCR Investment Xi LLC	director, 10 percent owner:	−12,735,301	$15.17
May 13, 2026	Warburg Pincus & Co.	director, 10 percent owner:	−19,102,952	$15.17
Mar 6, 2026	GTCR Investment Xi LLC	director, 10 percent owner:	−10,000,000	$15.27